Containing GS-441524 in an oral tablet form, NeoFipronis® (Pronidesivir) provides a quality-controlled and traceable veterinary product option for feline infectious peritonitis (FIP)-related treatment management.
Vientiane, Laos — March 2, 2026 — NeoFipronis® (Pronidesivir) has completed official registration in Laos and is now available through authorized channels as an oral GS-441524 veterinary tablet.
This official registration represents an important milestone in the development of NeoFipronis® (Pronidesivir), reflecting continued commitment to product standardization, quality control, and batch traceability.
NeoFipronis® is the brand name of Pronidesivir. As an oral veterinary product containing GS-441524, NeoFipronis® (Pronidesivir) is designed to support cats with feline infectious peritonitis (FIP) under veterinary guidance, while helping veterinarians and cat owners access a clearer and more verifiable product source.
For many years, FIP-related treatment products have faced challenges such as unclear product sources, inconsistent quality standards, and limited dosage transparency. Through official registration, batch traceability, and authorized-channel supply, NeoFipronis® (Pronidesivir) aims to reduce the potential risks associated with non-standard or unauthorized products.
The product is formulated as oral tablets and may be used under veterinary guidance according to the cat’s body weight, clinical type, and changes in condition. Compared with injectable formulations, oral tablets may help improve dosing convenience during long-term treatment and reduce daily administration stress for cats.
NeoFipronis® will continue to improve its product quality system, batch verification mechanism, and professional information support to provide more reliable product information and user support for the FIP treatment field.